• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by InflaRx N.V.

    4/27/23 4:01:16 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IFRX alert in real time by email
    6-K 1 brhc20052059_6k.htm 6-K
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    FORM 6-K


    Report of Foreign Private Issuer
    Pursuant to Rule 13a-16 or 15d-16
    of the Securities Exchange Act of 1934

    For the month of April 2023
    Commission File Number: 001-38283



    InflaRx N.V.

    (Translation of registrant's name into English)


    Winzerlaer Str. 2
    07745 Jena, Germany
    (Address of principal executive office)


    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F  ☒         Form 40-F ☐



    INFLARX N.V.

    Results of Annual General Meeting of Shareholders

    On April 26, 2023, InflaRx N.V. (the “Company”) held its Annual General Meeting of Shareholders (the “Annual General Meeting”). The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

    Agenda Item 3. Adoption of Dutch statutory annual accounts for the fiscal year ended December 31, 2022.

    The Company shareholders approved the adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2022.

    Agenda Item 5. Instruction to Ernst & Young Accountants LLP for the external audit of the Company’s annual accounts for the financial year 2023.

    The Company shareholders approved the instruction to Ernst & Young Accountants LLP for the external audit of the Company’s annual accounts for the financial year 2023.

    Agenda Item 6. Release from liability for the Company’s directors with respect to the performance of their duties during the fiscal year ended December 31, 2022.

    The Company shareholders approved the release from liability for the Company’s directors with respect to the performance of their duties during the fiscal year ended December 31, 2022.

    Agenda Item 7. Appointment of Ms. Hege Hellstrom as non-executive director of the Company.

    The Company shareholders approved the appointment of Ms. Hege Hellstrom as non-executive director of the Company.

    Agenda Item 8. Extension of authorization for the Company’s board of directors (the “Board”) to issue shares and grant rights to subscribe for shares.

    The Company shareholders approved the extension of authorization for the Board to issue shares and grant rights to subscribe for share.

    Agenda Item 9. Extension of authorization for the Board to limit and exclude pre-emption rights.

    The Company shareholders approved the extension of authorization for the Board to limit and exclude pre-emption rights.

    Agenda Item 10. Extension of authorization for the Board to acquire shares and depository receipts for shares in the Company’s capital.

    The Company shareholders approved the extension of authorization for the Board to acquire shares and depository receipts for shares in the Company’s capital.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     
    INFLARX N.V.
       
    Date: April 27, 2023
    By:
     
    /s/ Niels Riedemann
     
    Name:
    Niels Riedemann
     
    Title:
    Chief Executive Officer



    Get the next $IFRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IFRX

    DatePrice TargetRatingAnalyst
    5/29/2025$2.00Strong Buy → Outperform
    Raymond James
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/5/2023$8.00Neutral → Buy
    Guggenheim
    2/28/2022Buy → Neutral
    Guggenheim
    11/8/2021$14.00 → $15.00Strong Buy
    Raymond James
    10/28/2021$14.00Outperform → Strong Buy
    Raymond James
    8/6/2021$11.00 → $10.00Outperform
    Raymond James
    8/6/2021$2.80 → $2.50Underperform
    Credit Suisse
    More analyst ratings